Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Olivier Cussenot is active.

Publication


Featured researches published by Olivier Cussenot.


Histopathology | 2007

Profiling and classification tree applied to renal epithelial tumours

Yves Allory; C. Bazille; A. Vieillefond; Vincent Molinié; B. Cochand-Priollet; Olivier Cussenot; P. Callard; M. Sibony

Aims:u2002 Selection of the relevant combination from a growing list of candidate immunohistochemical biomarkers constitutes a real challenge. The aim was to establish the minimal subset of antibodies to achieve classification on the basis of 12 antibodies and 309 renal tumours.


The Journal of Steroid Biochemistry and Molecular Biology | 2008

Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa).

Frank Giton; Alexandre de la Taille; Yves Allory; Hervé Galons; Francis Vacherot; Pascale Soyeux; Claude Clément Abbou; Sylvain Loric; Olivier Cussenot; Jean-Pierre Raynaud; Jean Fiet

Seeking insight into the possible role of estrogens in prostate cancer (PCa) evolution, we assayed serum E2, estrone (E1), and estrone sulfate (E1S) in 349 PCa and 100 benign prostatic hyperplasia (BPH) patients, and in 208 control subjects in the same age range (50-74 years). E1 (pmol/L+/-S.D.) and E1S (nmol/L+/-S.D.) in the PCa and BPH patients (respectively 126.1+/-66.1 and 2.82+/-1.78, and 127.8+/-56.4 and 2.78+/-2.12) were significantly higher than in the controls (113.8+/-47.6 and 2.11+/-0.96). E2 was not significantly different among the PCa, BPH, and control groups. These assays were also carried out in PCa patients after partition by prognosis (PSA, Gleason score (GS), histological stage, and surgical margins (SM)). Significantly higher E1S levels were found in PCa with: PSA>10 ng/L (3.05+/-1.92) versus PSA<or=10 ng/mL (2.60+/-1.55), stage pT3-T4 (2.99+/-1.80) versus pT2 (2.58+/-1.58), and positive (3.26+/-1.95) versus negative margins (2.52+/-1.48). E1 was higher in poor- than in better-prognosis PCa. E2 was significantly higher in PCa with GS>or=4+3 (109.5+/-43.8) versus GS<or=3+4 (100.6+/-36.5) and increased significantly when GS increased from 3+3 to 4+4. Estrogens, especially E1S appeared to be possible markers of PCa progression. Attempting to identify potential sources of E2 in PCa according to prognosis, as well as in BPH, we found a significant correlation coefficient between E1S and E2 (0.266-0.347) in poor-prognosis PCa and no correlation in BPH (0.026) and better-prognosis PCa (0.013-0.104). It is as though during progression of PCa from good to poor prognosis there were a shift in the E1 to E2 metabolic pathway from predominantly oxidative to predominantly reductive.


The Journal of Steroid Biochemistry and Molecular Biology | 1996

Human prostatic cells in culture: Different testosterone metabolic profile in epithelial cells and fibroblasts from normal or hyperplastic prostates

Isabelle Berthaut; Marie-Claire Portois; Olivier Cussenot; Irène Mowszowicz

The prostate gland depends on androgens for its development and the maintainance of its differentiated structures and secretory function. We have characterized the metabolic pathways of testosterone in isolated epithelial (NE) and fibroblast cultured cells from normal (NF) and hyperplastic (BPHF) prostates, in order to provide a tool for the study of androgen function in the prostate in defined conditions. In NE, 5 alpha-reductase (5 alpha-R) is the predominant metabolic pathway whereas in NF 17 beta-hydroxysteroid dehydrogenase (17 beta-OHSDHase) is the main activity. However, 5 alpha-R in NF is 5-10-fold higher than in NE. Furthermore, a striking increase in both enzyme activities is observed in fibroblasts from hyperplastic prostates (5 alpha-R x 8; 17 beta-OHSDHase x 250 relative to NF). delta 4-androstenedione could serve as a reservoir for testosterone or could be a tentative protective mechanism directing testosterone metabolism towards an inactive molecule. In conclusion, human epithelial and stromal cells maintain in culture their main metabolic characteristics. The knowledge derived from these studies should facilitate the reconstitution and analysis of their interactions, which in vivo may modify their respective metabolism.


Journal of Histochemistry and Cytochemistry | 2007

Epithelial Phenotypes in the Developing Human Prostate

Guy Letellier; Marie-José Perez; Mokrane Yacoub; Pierre Levillain; Olivier Cussenot; Gaëlle Fromont

An intermediate population has been identified among prostate glands called transiently amplifying (TA) cells, which are characterized by coexpression of basal and luminal cytokeratins (CKs), high proliferation, and lack of p27 expression. These cells are rare in the normal adult prostate and increase in pretumoral conditions, but their importance in the developing gland remains unknown. We analyzed fetal prostates for the expression of CKs (5/6, 18, 19) and factors involved in proliferation and apoptosis: p63, Ki67, p27, epidermal growth factor (EGFR), Bcl2, androgen receptor (AR). Immunostaining was performed on a tissue microarray, including 40 prostates from fetuses aged 13-42 weeks and normal prostate tissue from 10 adults. In both solid buds and the basal compartment of canalized glands, cells expressed p63, CK5/6, CK19, CK18, BCL2, EGFR and were p27 negative. Luminal cells of fetal canalized glands continue to express CK19, EGFR, and BCL2, without p27 expression. In contrast, adult epithelial luminal cells showed diffuse AR and p27 expression, without CK19, BCL2, and EGFR staining. Proliferation was high and diffuse in fetal glands and rare and restricted to basal cells in adult glands. These results indicate that most fetal epithelial prostatic cells exhibit the phenotype of TA cells, suggesting their regulatory function in prostate development.


Archive | 1996

Laser-Induced Auto Fluorescence of Normal and Tumor Bladder Cells and Tissues

Maurice Anidjar; Olivier Cussenot; Jocelyne Blais; Olivier Bourdon; Sigrid Avrillier; Dominique Ettori; Jean-Marie Villette; Pierre Teillac; Alain Le Duc

Urothelial carcinoma in situ (CIS) is clearly related to tumor recurrence and subsequent cancer progression1. CIS detection remains a challenge for urologists since this lesion, which is only a few cell layers in thickness, may be asymptomatic and/or not visible under conventional white light cystoscopy.


Advances in Laser and Light Spectroscopy to Diagnose Cancer and Other Diseases III: Optical Biopsy | 1996

Assessment of different excitation wavelengths for photodetecting neoplastic urothelial lesions by laser-induced autofluorescence spectroscopy

Maurice Anidjar; Olivier Cussenot; Sigrid Avrillier; Dominique Ettori; Pierre Teillac; Alain Le Duc

We have designed a program using laser induced autofluorescence spectroscopy as a possible way to characterize urothelial tumors of the bladder. The autofluorescence spectra were compared between normal, suspicious and tumor areas of human bladder. Three different pulsed laser wavelengths were used for excitation: 308 nm (excimer), 337 nm (nitrogen) and 480 nm (dye laser). Excitation light was delivered by a specially devised multifiber catheter introduced through the working channel of a regular cystoscope under saline irrigation. The fluorescence light was focused into an optical multichannel analyzer detection system. The data was evaluated in 25 patients immediately before resection of a bladder tumor. Spectroscopic results were compared with histopathology. Upon 337 nm and 480 nm excitations, the overall intensity of the fluorescence spectra from bladder tumors was clearly reduced in comparison with normal urothelium, regardless of the stage and the grade of the tumor. upon 308 nm excitation, the shape of tumor fluorescence spectra, including carcinoma in situ, differed drastically from that of normal tissue. In this case, no absolute intensity measurements are needed and clear diagnosis can be achieved from fluorescence intensity ratio (360/440 nm). This spectroscopic study could be particularly useful for the design of a simplified autofluorescence imaging device for real-time routine detection of occult urothelial neoplastic lesions.


Genes, Chromosomes and Cancer | 1994

Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q

Alain Latil; J. C. Baron; Olivier Cussenot; Georges Fournier; Thierry Soussi; Laurent Boccon-Gibod; Alain Le Duc; Jacques Rouëssé; Rosette Lidereau


Urology | 2005

EFFECTS OF LONG-TERM FINASTERIDE TREATMENT ON PROSTATE CANCER MORPHOLOGY AND CLINICAL OUTCOME

Mark A. Rubin; Yves Allory; Vincent Molinié; Xavier Leroy; Hugo Faucon; Francis Vacherot; Wei Huang; Adam Kuten; Laurent Salomon; Xavier Rebillard; Olivier Cussenot; Claude Clément Abbou; Alexandre de la Taille


Archive | 2001

Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre

Karine Chantrel-Groussard; Olivier Cussenot; Alain Latil


Archive | 2001

Method for in vitro diagnosis of prostatic cancer and kit therefor

Olivier Cussenot; Alain Latil; Karine Chantrel-Groussard

Collaboration


Dive into the Olivier Cussenot's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antoine Valeri

Institut Universitaire de France

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Georges Fournier

Institut Universitaire de France

View shared research outputs
Researchain Logo
Decentralizing Knowledge